

Douglas A Stewart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/253928/publications.pdf>

Version: 2024-02-01

67
papers

1,103
citations

566801

15
h-index

414034

32
g-index

67
all docs

67
docs citations

67
times ranked

1933
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	13.9	298
2	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
3	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
4	Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2012, 18, 4962-4972.	3.2	62
5	Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. <i>Blood</i> , 2003, 102, 377-387.	0.6	58
6	Immune Cell Subset Counts Associated with Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 450-462.	2.0	48
7	Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 764-771.	2.0	46
8	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	1.7	43
9	Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1654-1663.	2.0	40
10	Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 4623-4627.	0.6	32
11	Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 957-967.	2.3	24
12	Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2064-2070.	0.6	22
13	CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. <i>Journal of Clinical Pathology</i> , 2015, 68, 844-848.	1.0	22
14	Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 37-46.	2.0	22
15	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. <i>Blood Advances</i> , 2019, 3, 797-812.	2.5	22
16	pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1276-1282.	0.6	16
17	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. <i>Leukemia and Lymphoma</i> , 2019, 60, 133-141.	0.6	16
18	Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2016, 57, 28-33.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 161-170.	1.1	13
20	Osetamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 532-535.	1.5	13
21	Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. <i>Leukemia and Lymphoma</i> , 2011, 52, 2124-2129.	0.6	12
22	Targeting non-Hodgkin lymphoma with blinatumomab. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1013-1017.	1.4	12
23	Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1505-1510.	2.0	10
24	Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) -1 Scores Predict Improved Outcome. <i>Blood</i> , 2010, 116, 687-687.	0.6	9
25	Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341987942.	0.6	7
26	Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada. <i>Blood</i> , 2020, 136, 26-27.	0.6	7
27	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 941-948.	2.0	6
28	Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 323-331.	0.5	6
29	Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. <i>Leukemia and Lymphoma</i> , 2022, 63, 583-590.	0.6	5
30	PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage. <i>Hematological Oncology</i> , 2015, 33, 159-165.	0.8	4
31	A Prospective Phase II Study of RICE Re-Induction, Then High-Dose Fludarabine and Busulfan, Followed by Autologous or Allogeneic Blood Stem Cell Transplantation for Indolent B-Cell Lymphoma. ClinicalTrials.gov ID: NCT00144092 . <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 475-482.	0.2	3
32	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1417-1427.	0.9	3
33	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
34	Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada. <i>Blood</i> , 2012, 120, 2003-2003.	0.6	3
35	Physician perspectives on delays in cancer diagnosis in Alberta: a qualitative study. <i>CMAJ Open</i> , 2021, 9, E1120-E1127.	1.1	3
36	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 829-835.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SpiRel Study. <i>Blood</i> , 2020, 136, 16-16.	0.6	2
38	High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.. <i>Blood</i> , 2006, 108, 313-313.	0.6	2
39	Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. <i>Blood</i> , 2011, 118, 590-590.	0.6	2
40	Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4376-4376.	0.6	2
41	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. <i>Blood</i> , 2021, 138, 2525-2525.	0.6	2
42	Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. <i>Leukemia and Lymphoma</i> , 2022, 63, 2444-2452.	0.6	2
43	In Vitro and In Vivo Anti Lymphoma Effect of GX15-070 in Mantle Cell Lymphoma.. <i>Blood</i> , 2006, 108, 4756-4756.	0.6	1
44	Gaps in Access to Patient Care for Patients with Rare Hematological Disorders. <i>Blood</i> , 2011, 118, 4752-4752.	0.6	1
45	Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement. <i>Blood</i> , 2021, 138, 2912-2912.	0.6	1
46	NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome. <i>Scientific Reports</i> , 2022, 12, 8294.	1.6	1
47	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. <i>Clinical Pharmacokinetics</i> , 2020, 59, 7-23.	1.6	0
48	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2492-2496.	0.6	0
49	Prophylactic high-dose methotrexate in diffuse large <sc>B</sc> cell lymphoma, authors' response. <i>American Journal of Hematology</i> , 2021, 96, E339-E341.	2.0	0
50	Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2021, , 1-3.	0.6	0
51	Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.. <i>Blood</i> , 2004, 104, 2313-2313.	0.6	0
52	A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) REß Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkinß Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 915-915.	0.6	0
53	Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.. <i>Blood</i> , 2005, 106, 2932-2932.	0.6	0
54	Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.. <i>Blood</i> , 2005, 106, 1763-1763.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.. Blood, 2006, 108, 3140-3140.	0.6	0
56	Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.. Blood, 2006, 108, 2865-2865.	0.6	0
57	FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.. Blood, 2009, 114, 3384-3384.	0.6	0
58	Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179. Blood, 2011, 118, 500-500.	0.6	0
59	Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience. Blood, 2020, 136, 17-18.	0.6	0
60	Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study. Blood, 2020, 136, 17-18.	0.6	0
61	Comparison of the Management and Short-Term Outcomes between Patients with Advanced Cancer and Other End-of-Life Conditions Presenting to Two Canadian Emergency Departments. Journal of Palliative Medicine, 2022, , .	0.6	0
62	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
63	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
64	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
65	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
66	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
67	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0